For families and patients wanting more information about Allo Phase 2 Alzheimer’s Clinical Trial: LEARN MORE

Troubled by hot flashes? Learn more about the HF Relief Study being conducted at the University of Arizona to test the effectiveness of a natural product, PhytoSERM, to alleviate hot flashes:

For information about the PhytoSERM Brain Clinical Trial: LEARN MORE

Can the Alzheimer’s Brain Regenerate and Recover?

The University of Arizona Center for Innovation in Brain Science has received a $37.5M grant from the National Institutes of Health to research a potential regenerative therapy for Alzheimer’s disease.

 A team led by Roberta Diaz Brinton, PhD, director of the Center for Innovation in Brain Science, received the multi-million dollar grant from the National Institute on Aging. The five-year grant will fund a national multi-site Phase 2 clinical trial to determine the effectiveness of allopregnanalone, or allo, as a treatment for individuals with early-stage Alzheimer’s who carry the genetic risk factor for the disease. This award supports the goals of the National Alzheimer’s Project Act.

 “Based on our discovery and early clinical research findings, we are optimistic that allo could be an effective treatment for Alzheimer’s,” Brinton said. “Our precision medicine approach for Alzheimer’s is designed to treat the right person at the right time. Specifically, our clinical trial of allo will focus on those with early-stage Alzheimer’s who have the genetic risk factor for the disease. We are thrilled to advance allo as the first regenerative therapeutic for Alzheimer’s and to bring innovations in the brain science of the future to those who need a cure today.”

 Currently, there are not any effective treatments for Alzheimer’s. As the global population ages, greater urgency exists to develop therapeutics that will prevent and treat this devastating disease.

 “Dr. Brinton and her team are spearheading innovative clinical research that is vital to advance our pursuit of cures for neurodegenerative diseases such as Alzheimer’s,” said UA President Robert C. Robbins, MD. “This work has the potential to have a direct impact on the health and quality of life of millions of people. The University of Arizona is where innovation happens, and the clinical trial of allo as the first potential regenerative therapeutic for Alzheimer’s is a great example of our transformative DNA.”

 More than 5 million Americans and 50 million people worldwide are living with Alzheimer’s, according to the Alzheimer’s Association. By 2050, that number is expected to increase to 14 million Americans. In Arizona, more than 200,000 people age 65 and older will be living with the disease by 2025.

 “Dr. Brinton’s research has the potential to bring relief to the millions of people who are living with Alzheimer’s and to the countless more family members who are experiencing these effects in a loved one,” said Elizabeth Cantwell, PhD, UA senior vice president for research and innovation. “Research that comes out of the labs and truly makes a difference in the everyday lives of people is one of the core principles of research at the University of Arizona.”

 This research is supported by the National Institute on Aging of the National Institutes of Health under Award No: R01AG063826.

The Center for Innovation in Brain Science (CIBS) at the University of Arizona is addressing the challenge that, in the 21st century, there is not a single cure for a single neurodegenerative disease and is focused on four age-associated neurodegenerative diseases: Alzheimer’s, Parkinson’s, Multiple Sclerosis and ALS.

© 2024 Center for Innovation Brain Science. University of Arizona Health Sciences.

Skip to content